Bio Usawa, in collaboration with Pacific Environmental Technologies of Corona, CA, is setting a new standard for producing lifesaving antibody–based therapies through its novel BioMod™ modular facility. The first BioMod unit, having completed initial qualification, is now beginning its journey to its final location in Kigali, Rwanda.

BioMod represents a highly novel advancement in biotech manufacturing. BioMod units are built to eliminate unnecessary duplication, oversizing, and complexity to yield reproducible, sustainable GMP – quality biotherapies in a very small footprint.

“It has been a joy to see the first BioMod to its completion and shipment to the Continent,” remarked BioUsawa’s Chief of Staff, Elise Brownell, PhD. “This marks a significant achievement for Bio Usawa, and, more importantly, represents a new paradigm for making high quality biotherapies accessible to patients in Africa and beyond.”